http://www.unboundmedicine.com/medline/ebm/research/carboplatinUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19892746/full_citation/Phase_I_dose_finding_study_of_paclitaxel_with_panitumumab_carboplatin_and_intensity_modulated_radiotherapy_in_patients_with_locally_advanced_squamous_cell_cancer_of_the_head_and_neck_Wirth LJ, Allen AM, Posner MR, et al. 
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. [JOURNAL ARTICLE]
Ann Oncol 2009 Nov 5.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19889612/full_citation/A_phase_I_open_label_dose_escalation_study_of_oral_BIBF_1120_combined_with_standard_paclitaxel_and_carboplatin_in_patients_with_advanced_gynecological_malignancies_du Bois A, Huober J, Stopfer P, et al. 
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. [JOURNAL ARTICLE]
Ann Oncol 2009 Nov 4.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19887966/full_citation/Phase_II_Trial_of_Nanoparticle_Albumin_Bound_Paclitaxel_Carboplatin_and_Bevacizumab_in_First_line_Patients_with_Advanced_Nonsquamous_Non_small_Cell_Lung_Cancer_Reynolds C, Barrera D, Jotte R, et al. 
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer. [JOURNAL ARTICLE]
J Thorac Oncol 2009 Oct 31.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19887545/full_citation/Small_molecule_inhibition_of_Wee1_kinase_by_MK_1775_selectively_sensitizes_p53_deficient_tumor_cells_to_DNA_damaging_agents_Hirai H, Iwasawa Y, Okada M, et al. 
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. [JOURNAL ARTICLE]
Mol Cancer Ther 2009 Nov 3.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19885006/full_citation/Antitumor_Effects_of_Camptothecin_Combined_with_Conventional_Anticancer_Drugs_on_the_Cervical_and_Uterine_Squamous_Cell_Carcinoma_Cell_Line_SiHa_Ha SW, Kim YJ, Kim W, et al. 
Antitumor Effects of Camptothecin Combined with Conventional Anticancer Drugs on the Cervical and Uterine Squamous Cell Carcinoma Cell Line SiHa. [JOURNAL ARTICLE]
Korean J Physiol Pharmacol 2009 Apr; 13(2):115-121.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19884853/full_citation/Chemotherapy_Associated_Toxicity_in_a_Large_Cohort_of_Elderly_Patients_with_Non_small_Cell_Lung_Cancer_Hardy D, Cormier JN, Xing Y, et al. 
Chemotherapy-Associated Toxicity in a Large Cohort of Elderly Patients with Non-small Cell Lung Cancer. [JOURNAL ARTICLE]
J Thorac Oncol 2009 Oct 30.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19884554/full_citation/Randomized_Phase_III_Trial_of_Gemcitabine_Based_Chemotherapy_With_In_Situ_RRM1_and_ERCC1_Protein_Levels_for_Response_Prediction_in_Non_Small_Cell_Lung_Cancer_Reynolds C, Obasaju C, Schell MJ, et al. 
Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non-Small-Cell Lung Cancer. [JOURNAL ARTICLE]
J Clin Oncol 2009 Nov 2.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19879055/full_citation/Second_line_treatment_for_malignant_pleural_mesothelioma_Ceresoli GL, Zucali PA, Gianoncelli L, et al. 
Second-line treatment for malignant pleural mesothelioma. [JOURNAL ARTICLE]
Cancer Treat Rev 2009 Oct 28.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19879013/full_citation/Is_neoadjuvant_chemoradiotherapy_a_feasible_strategy_for_stage_IIIA_N2_non_small_cell_lung_cancer_Mature_results_of_the_randomized_IFCT_0101_phase_II_trial_Girard N, Mornex F, Douillard JY, et al. 
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. [JOURNAL ARTICLE]
Lung Cancer 2009 Oct 28.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19875975/full_citation/Phase_II_Trial_of_Irinotecan_Carboplatin_and_Bevacizumab_in_the_Treatment_of_Patients_with_Extensive_Stage_Small_Cell_Lung_Cancer_Spigel DR, Greco FA, Zubkus JD, et al. 
Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer. [JOURNAL ARTICLE]
J Thorac Oncol 2009 Oct 28.
Abstract | Full Citation